×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

×ðÁú¿­Ê±ÓëÄúÏàÔ¼µÚÈý½ì¹ú¼ÊÉúÎïÒ½Ò©¹¤ÒµÉú³¤´ó»á

2024-09-06
|
»á¼ûÁ¿£º

9ÔÂ12ÈÕ-14ÈÕ£¬µÚÈý½ì¹ú¼ÊÉúÎïÒ½Ò©¹¤ÒµÉú³¤´ó»á½«ÔÚÉϺ£ÄϽ¼±ö¹Ý¾ÙÐС£´ó»á½«Í¨¹ýÖ÷Ìⱨ¸æ¡¢Ô²×À¶Ô»°µÈ½»Á÷ÐÎʽ£¬Ì½ÌÖÁ¢ÒìÒ©Îï·¢Ã÷¡¢¿¹Ìå¡¢ÒßÃçÓëÉúÎïÖÎÁÆÐÂÁÆ·¨¡¢¿¹Ö×ÁöÕïÁƵÄÐÂÕ½ÂÔºÍÐÂÊÖÒÕ¡¢ÂѰ×Öʼ°¶àëÄÊÖÒÕÇ°ÑØÓ빤ҵӦÓá¢ÌÇÄò²¡¼°·ÊÅÖ´úл¼²²¡ÕïÖÎÐÂÊÖÒÕºÍÐÂÁÆ·¨¡¢ÐÂÐÍÃ¸ÖÆ¼ÁµÄ´´ÔìÓ빤ҵ»¯µÈÐÐÒµÈÈÃÅ»°Ìâ¡£

×ðÁú¿­Ê±×÷Ϊ±¾½ì´ó»áµÄЭ°ìµ¥Î»£¬½«·ºÆðÓ¢²Å¡°É½º£»á¡±Ô²×ÀÂÛ̳¡£±ðµÄ£¬×ðÁú¿­Ê±×¨¼Ò½«ÔÚÖ÷ÂÛ̳¼°×¨Ìâ·ÖÂÛ̳ÉÏ´øÀ´¾«²Ê·ÖÏí£¬Ï£Íûͨ¹ý´Ë´ÎÔ˶¯½øÒ»²½¼ÓÉî×ðÁú¿­Ê±ÓëÒ½Ò©ÐÐÒµÊ×ÄÔ¡¢×¨¼ÒѧÕß¼äµÄ½»Á÷£¬·ÖÏí×ðÁú¿­Ê±×îÐÂÊÖÒÕÆ½Ì¨ºÍÒ»Ö±¾«½øµÄÁÙ´²Ç°Ñз¢Ð§ÀÍÄÜÁ¦¡£

ÎÒÃǽ«È«³ÌÔÚB5ÉèÕ¹£¬³ÏÑûݰÁÙ½»Á÷£¡

µÚÈý½ì¹ú¼ÊÉúÎïÒ½Ò©¹¤ÒµÉú³¤´ó»áչλ.webp

¾Û»áËùÔÚ£ºÉϺ£ÄϽ¼±ö¹Ý£¨·îÏÍÇøÍû԰·8ºÅ£©

×ðÁú¿­Ê±Ó¢²Å"ɽº£»á"Ô²×ÀÂÛ̳

×ðÁú¿­Ê±×÷Ϊ±¾½ì´ó»áµÄЭ°ìµ¥Î»£¬½«·ºÆðÓ¢²Å¡°É½º£»á¡±Ô²×ÀÂÛ̳£¬×ðÁú¿­Ê±Ê×ϯ¿ÆÑ§¹ÙÅíË«Çå½ÌÊÚÁªºÏÖ÷³Ö£¬Ê×ϯÉÌÎñ¹Ù²Ì½ðÄȲ©Ê¿³öϯ¶Ô»°£¬²¢Ô¼ÇëÀ´×ÔѧÊõ½ç¡¢¹¤Òµ½çºÍͶ×ʽçµÄ¶¥¼âר¼Ò·ÖÏí¿´·¨ºÍÂÄÀú¡£

ʱ¼ä£º9ÔÂ13ÈÕ  08:30-11:50
ËùÔÚ£ºÒ»Â¥·ïÑôÐù

Éϰ볡£º08:30-10:15
Ö÷³ÖÈË£ºÐì¾ü£¬ÃÀ¹úBIORICH¹«Ë¾¶­Ê³¤

²Î»á¼Î±ö£º
ÕÅÐ÷Ä£¬ÄÏ·½¿Æ¼¼´óѧƺɽÉúÎïÒ½Ò©Ñо¿ÔºÔº³¤
Ф¹ðɽ£¬ÉîÛÚδÀ¶×ª»¯Ò½Ñ§Ñо¿ÔºÔº³¤
ÕÅÒúÉú£¬ÎÞÎý±´ËþÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾Ê×ϯ¿Æ¼¼¹Ù
÷µÂÊ¢£¬ËÕÖݹú¿ïÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾¶­Ê³¤
Ê¢¾Õ»¨£¬º£Õ飨ÉϺ££©ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾¶­Ê³¤
ÐìºìÑÒ£¬¼ª¶ûÉú»¯£¨ÉϺ££©ÓÐÏÞ¹«Ë¾¶­Ê³¤
ÏÄ Ñô£¬±±¾©Ôªº½×ÊÔ´ºÏ×ÊÈË
ÕŻݱó£¬ÖйúÒ©¿Æ´óѧ½ÌÊÚ
ÇñÇàËÉ£¬¸ßÄÜ×ÊÔ´¸±×ܲÃ
÷Ïþµ¤£¬°Ù°ÂÌ©¼¯ÍŶ­Ê³¤
»ÆÔ¾½ø£¬ÉϺ£èîÃÉÉúÎïÊÖÒÕÓÐÏÞ¹«Ë¾¶­Ê³¤
×ÞÖ¾ÑÖйúÈ«Çò¿µ½¡Ò©ÎïÑз¢ÖÐÐÄÖ÷ÈÎ

ϰ볡£º10:30-11:50
Ö÷³ÖÈË£ºÅíË«Ç壬×ðÁú¿­Ê±Ê×ϯ¿ÆÑ§¹Ù

²Î»á¼Î±ö£º
×ÞÁéÁú£¬ËÕÖÝ¿µÎ¬Ñ¶ÉúÎïÊÖÒÕ¶­Ê³¤
Âí¿ª¹ú£¬ÀÊ»ªÖÆÒ©CEO£»Î¬ÑÇÉúÎï¸ß¼¶¸±×ܲÃ
Íõ ´Ô£¬Âõ½Üת»¯Ò½Ñ§Ñо¿£¨ËÕÖÝ£©ÓÐÏÞ¹«Ë¾¸ß¼¶¸±×ܲÃ
²Ì½ðÄÈ£¬ÉϺ£×ðÁú¿­Ê±ÉúÎïÒ½Ò©ÓÐÏÞ¹«Ë¾Ê×ϯÉÌÎñ¹Ù
ÁõÃÏÔª£¬Á¢ÔªÉúÎïÒ½Ò©ÊÖÒÕÓÐÏÞ¹«Ë¾£¬¶­Ê³¤¼æCEO
κ¼ÌÒµ£¬ËÕÖÝΩÓÓ»ùÒòÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾¶­Ê³¤
Ç® êÍ£¬½­ËÕ´óѧҽѧԺ½ÌÊÚ
Áº Íþ£¬ÉϺ£ÓòÔÆÒ½ÁÆ¿µ½¡¿Æ¼¼ÓÐÏÞ¹«Ë¾Ê×´´ÈË¡¢CEO
ÂíÐËÔª£¬»ª¶«Àí¹¤´óѧ½ÌÊÚ
ÕÅÑ϶¬£¬ÉîÛÚ¿ªÔÃÉúÃü¿Æ¼¼ÓÐÏÞ¹«Ë¾Ê×ϯ¿ÆÑ§¹Ù
³Âº£Ï¼£¬Ìì½ò´óѧҩÎï¿ÆÑ§ÓëÊÖÒÕѧԺ½ÌÊÚ
ÑÌΣ¬ÄÏ·½¿Æ¼¼´óѧϸ°ûÓë»ùÒòÖÎÁÆÑо¿ÖÐÐĽÌÊÚ£»Èðôà°ÂÄÉ£¨ÉîÛÚ£©ÉúÎïÒ½Ò©ÓÐÏÞ¹«Ë¾Ê×´´ÈË

×ðÁú¿­Ê±×¨¼Ò¼´½«·ÖÏí

ÅíË«Çå  ½ÌÊÚ.webp

ÅíË«Çå ½ÌÊÚ ×ðÁú¿­Ê±Ê×ϯ¿ÆÑ§¹Ù

±±¾©´óѧԤ·Àҽѧ²©Ê¿ºó¡¢Öйú¶¾Àíѧ»á¸±Àíʳ¤¡¢ÃÀ¹úÃÜÎ÷¸ùÖÝÁ¢´óѧҩÀíѧ²©Ê¿ºó¡£ºã¾Ã´ÓÊÂÐÂÒ©´´ÔìÁÙ´²Ç°Ñо¿£¬¼ç¸ºGLPÊÖÒÕÆ½Ì¨½¨Éè¡£½ÒÏþ¿ÆÑÐÂÛÎÄ300ÓàÆª£¨SCIÂÛÎÄ100ÓàÆª£©£¬Ö÷±à²Î±à׍ָ13²¿¡£»ñÊ¡²¿¼¶¿Æ¼¼½±12Ï»ñÖйú¿ÆÐ­¡°ÌìÏÂÓÅÒì¿Æ¼¼ÊÂÇéÕß¡±ÉùÓþ³Æºô¡¢Öйú¶¾ÀíѧÓÅÒìТ˳½±¡£×÷Óý˶ʿ¡¢²©Ê¿¼°²©Ê¿ºó90¶àÃû¡£¼æÈÎʳÎïÒ©Æ·¼àÊÓÖÎÀí¾ÖÐÂÒ©ÉóÆÀר¼Ò¡¢Ò½ÁÆÆ÷еÉóÆÀר¼Ò¡¢»·±£²¿ÐÂÎïÖÊÉóÆÀר¼Ò¼°ETAP¸±Ö÷±àµÈѧÊõÖ°Îñ¡£

¶Ô»°Ö÷Ì⣺The Future of Biopharma: Navigating Innovation, Regulation, and Global Collaboration
ËùÔÚ£º  Ò»Â¥»ª²ýÌü Ö÷ÂÛ̳
ʱ¼ä£º 9ÔÂ12ÈÕ 12:00-12:30

Íõµ¤  ²©Ê¿.webp

Íõµ¤ ²©Ê¿ ×ðÁú¿­Ê±ÐÂÒ©×¢²á²¿×ܼà&ÖÆ¼Á²¿¸ß¼¶Ö÷ÈÎ

Íõµ¤£¬ÉòÑôÒ©¿Æ´óѧ±¾¿Æ£¬ÉϺ£½»Í¨´óѧ˶ʿ£¬¸´µ©´óѧ²©Ê¿£¬ÔÚÒ©ÆóÓÐÊ®ÓàÄêÑз¢ÂÄÀú£¬ÔøÏòµ¼ÍŶÓ×éÖ¯¹ý¶à¸öÏîÄ¿µÄ×¢²áÉ걨£¬ÊìϤÐÂÒ©CMCºÍÁÙ´²Ç°ÆÀ¼ÛÀú³Ì£¬ÒÔ¼°Ò©ÎïµÄÁÙ´²ÆÀ¼ÛÀú³Ì£¬ÄÜÔÚÁ¢ÒìÒ©×¢²áÉ걨սÂÔÒÔ¼°Ò©Î↑·¢Ê±´ú£¬Ìṩ¸üºÃµÄ¹æÔòºÍÊÖÒÕÖ§³Ö¡£

·ÖÏíÖ÷Ì⣺BL-602, A Cyclophilin Inhibitor, Reduces Fibrosis and Proteinuria in Chronic Kidney Disease
ËùÔÚ£º  Ò»Â¥»ª²ýÌü Ö÷ÂÛ̳
ʱ¼ä£º 9ÔÂ12ÈÕ 11:35-11:55

Ô¬ÔÆÔÆ  ²©Ê¿.webp

Ô¬ÔÆÔÆ ²©Ê¿ ×ðÁú¿­Ê±Ò©Ð§²¿ÏîĿ˾Àí

ÉϺ£ÖÐÒ½Ò©´óѧ²©Ê¿£¬Ö÷Òª´ÓÊ·ÇÖ×ÁöÒ©ÎïµÄÁÙ´²Ç°ÌåÄÚҩЧѧÆÀ¼ÛÊÂÇ飬Ñо¿ÄÚÈݰüÀ¨´úлÐÔ¼²²¡¡¢ÄÔ×äÖС¢¾«Éñ¼²²¡ÒÔ¼°Ñ×Ö¢ÃâÒßÀ༲²¡µÄ¶¯ÎïÌåÄÚҩЧѧ¼°Ò©Àí»úÖÆÑо¿¡£ÏÖÔÚÔÚ×ðÁú¿­Ê±Ñз¢Æ½Ì¨¼ÓÈë²¢Íê³É°ÙÓàÏîÏà¹ØÐÂÒ©Ñз¢ÏîÄ¿£¬ËùÈÏÕæµÄ¶à¸öÏîÄ¿ÒÑÍê³Éº£ÄÚÍâINDÉ걨¡£

·ÖÏíÖ÷Ì⣺Animal Models of Human Diseases and the Application in Pharmacodynamic Studies
ËùÔÚ£º  Ò»Â¥¾Û»áÊÒ5B  IDDST02-¼²²¡Ä£×ÓÓëÓ¦ÓÃ
ʱ¼ä£º 9ÔÂ12ÈÕ 14:05-14:30

´ó»áÏêÇé¸ÅÀÀ

µÚÈý½ì¹ú¼ÊÉúÎïÒ½Ò©¹¤ÒµÉú³¤´ó»áչλ´ó¾Û»áÌâ.webp

ÁªÏµ×ðÁú¿­Ê±

ÈçÄúÏ£ÍûÔÚÏÖ³¡Óë×ðÁú¿­Ê±×¨¼ÒÅöÃæ
½Ó´ýÁªÏµ×ðÁú¿­Ê±Ô¤Ô¼°²ÅÅ

ɨÂëÔÚÏßÁªÏµ.webp

ɨÂëÔÚÏßÁªÏµ
ÁªÏµÓÊÏ䣺marketing@medicilon.com.cn

Ïà¹ØÐÂÎÅ
ÉúÎïÒ½Ò©¹¤Òµ²½ÈëÉú³¤¿ì³µµÀÒýÖÚ¶àͶ×ÊÕß¹Ø×¢
2017-11-27
Ò½Ò©Ñз¢ÊÇÒ»¸öµä·¶µÄÖÜÆÚ³¤¡¢Í¶×Ê´óµÄÔ˶¯£¬¾­ÓÉǰЩÄêµÄÖØµãͶÈëºÍ¶¦Á¦´ó¾Ù¹¥¹Ø£¬º£ÄÚÖØµãÒ©ÆóµÄÒ»ÅúÐÂÒ©¼´½«½øÈë¡°ÊÕ»ñÆÚ¡±¡£ÒÔA¹ÉΪÀý£¬¸´ÐÇÒ½Ò©ÌåÏÖ£¬ÏÖÔÚÔÚÖ×Áö¡¢×ÔÉíÃâÒßÐÔ¼²²¡·½Ã棬ÓÐ8¸ö²úÆ·»ñ11¸öÈ«ÇòÁÙ´²Åú¼þ¡£ºãÈðÒ½Ò©²Æ±¨ÏÔʾ£¬½ñÄêÉϰëÄ깫˾ÀÛ¼ÆÍ¶ÈëÑз¢×ʽð7.8ÒÚÔª£¬Í¬±ÈÔöÌí60%£¬»ù±¾ÐγÉÁËÿÄê¶¼ÓÐÁ¢ÒìÒ©ÉêÇëÁÙ´²µÄÁ¼ÐÔÉú³¤Ì¬ÊÆ¡£
ÉúÎïÒ½Ò©¹¤ÒµÊг¡±¨¸æ£ºÒ½Ò©ÉÏÊй«Ë¾Òµ¼¨ÔöÌíÌ¬ÊÆÓÅÒì
2016-09-19
2016ÄêÉϰëÄêÒ½Ò©ÐÐÒµÓªÊÕͬ±ÈÔöÌí10%£¬Î»¾Ó¹¤Òµ¸÷ÐÐÒµÔöËÙǰÏߣ¬ÊÕÈëÔöËÙÓÐËùÆóÎÈ¡£ÐÐҵëÀûÂʺÍÖ÷ÓªÓªÒµÀûÈóÂÊͬ±È¾ùÓÐËùÌá¸ß£¬·´Ó¦ÁËÐÐÒµ½Ï¸ßµÄÓ¯ÀûÄÜÁ¦¡£
ÉϺ£ÊÐÉúÎïÒ½Ò©¹¤ÒµÉú³¤Ðж¯ÍýÏ루2014-2017Ä꣩
2015-08-04
ÉúÎïÖÆÒ©£º¶¦Á¦´ó¾ÙÉú³¤¿¹Ö×Áö¡¢¿¹Àà·çʪµÈ¿¹ÌåÒ©Î¼ÓËÙÖÎÁÆÐÔ»ùÒò¹¤³ÌÒßÃçµÄÑз¢£¬Æð¾¢Íƶ¯¿¹Ö×ÁöºÍÖÎÁÆÐÄË¥µÈÖØ×éϸ°ûÒò×ÓÒ©ÎïµÄ¹¤Òµ»¯£¬Ì½Ë÷Ö§³ÖºËËáÒ©Îï¡¢¸Éϸ°ûµÈÇ°ÑØÊÖÒÕÁ¢Ò죬·¢¶¯ÉϺ£ÉúÎïÖÆÒ©¹¤ÒµµÄ¿ìËÙÉú³¤£¬µ½2017Äêµ×£¬ÊµÏÖÖ÷ÓªÓªÒµÊÕÈë180ÒÚÔª¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿